Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Invasive mucinous adenocarcinoma (IMA) is a rare malignant tumor of the lung, characterized as a distinct subtype of lung adenocarcinoma, with unique histological features and clinical behavior. Because the diagnosis is often delayed due to its imaging characteristics resembling pneumonia, this neoplasm is associated with a poor prognosis.

Case Presentation: This case report describes a 69 years-old man who underwent an asymptomatic health examination, during which small ground-glass opacities were found in the periphery of both lungs. There was no significant change in the lesions during the subsequent 2 years follow-up. However, at the third year of follow-up, the lesions had significantly enlarged. A CT-guided puncture biopsy was performed, and the pathological results indicated IMA of the lung. Subsequently, the patient underwent surgical treatment, and the postoperative pathological findings were consistent with those of the biopsy. In this case, the patient believed that he had been following the doctor's orders for asymptomatic health checks and follow-up reexamination, yet his cancer diagnosis was still significantly delayed. Therefore, the patient demanded that the doctor take medical responsibility for the alleged negligence. After the doctor carefully described the imaging features of lung IMA, the patient ultimately decided to forgo pursuing medical responsibility and expressed satisfaction with the doctor's diagnosis.

Conclusion: This case illustrates the evolving imaging signs of lung IMA. Medical professionals should avoid diagnosing lung cancer as pneumonia, with the aim of enhancing the accuracy of early diagnosis and assisting in clinical evaluation. Additionally, it serves as a reference for patients to better understand this disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198235PMC
http://dx.doi.org/10.3389/fmed.2025.1578874DOI Listing

Publication Analysis

Top Keywords

case report
8
lung cancer
8
cancer pneumonia
8
invasive mucinous
8
mucinous adenocarcinoma
8
diagnosis delayed
8
asymptomatic health
8
medical responsibility
8
lung ima
8
lung
7

Similar Publications

Background: Pheochromocytomas and paragangliomas (PPGLs) are rare catecholamine-secreting neuroendocrine tumors originating from the embryonic neural crest. Approximately 30% of PPGLs are hereditary and are frequently associated with genetic syndromes, including neurofibromatosis type 1 (NF1). Composite PPGLs, which include components of both PPGLs and related tumors such as ganglioneuromas, are extremely rare in NF1 patients.

View Article and Find Full Text PDF

Salivary Duct Carcinoma Spread to the Internal Auditory Canal Along the Facial Nerve: A Case Report.

J Craniofac Surg

September 2025

Department of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Air Force Military Medical University, Xi'an, China.

Salivary duct carcinoma (SDC) is a rare high-grade parotid malignancy prone to perineural spread. However, perineural spread of SDC has rarely been reported. The case of a 46-year-old male with SDC spread along the facial nerve (FN) is presented here.

View Article and Find Full Text PDF

Scalp masses are common scalp lesions, most of which are benign, with a small proportion being malignant. Scalp sarcomas constitute one category of malignant tumors, primarily including fibrosarcoma, liposarcoma, rhabdomyosarcoma, and leiomyosarcoma. Among these, scalp leiomyosarcoma is exceedingly rare.

View Article and Find Full Text PDF

Bevacizumab for refractory gastrointestinal angiodysplasia: a case report and literature review.

Eur J Gastroenterol Hepatol

August 2025

Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar.

Currently, symptomatic gastrointestinal (GI) angiodysplasia is treated with argon plasma coagulation (APC) via endoscopic procedures, supplemented with octreotide or thalidomide treatment. However, suboptimal response and side effects are often seen. Bevacizumab, an angiogenesis inhibitor, may provide an alternative systemic therapy for patients with refractory GI angiodysplasia.

View Article and Find Full Text PDF